CAAS Capital Management’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-3,750
Closed -$503K 1347
2021
Q1
$503K Buy
+3,750
New +$475K 0.01% 920

Other funds holding ASLN

CAAS Capital Management's ASLN Position: Q2 2021 in Review

CAAS Capital Management sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q2 2021, closing a stake of 3,750 shares — an estimated $503K sold.

CAAS Capital Management first reported a position in ASLN in Q1 2021 and held it in 1 quarter. The position peaked at $503K in Q1 2021. 31 funds tracked by Wall St. Rank hold ASLN as of Q2 2021.

  • CAAS Capital Management reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 3,750 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q2 2021, an estimated $503K.
  • CAAS Capital Management first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $503K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.